Compounded vs. Research Peptides: What's Legal and What's Safe in 2026
The difference between a compounded peptide prescription and a gray-market 'research' peptide is the difference between regulated and unregulated. Here's what changed in 2026.
By Anthivera Editorial · Updated · 1 min read
Awaiting medical reviewDraft
Status: Stub. Outline is in place per
/docs/CONTENT-PLAN.md(Article 8).
The three buckets#
Section content TBD. FDA-approved drugs / compounded preparations / "research chemicals."
What compounding actually is#
Section content TBD. 503A (patient-specific) vs. 503B (outsourcing facilities); physician prescription required.
What "research use only" peptides really are#
Section content TBD. Sold "not for human consumption," unregulated for purity and dosing, legal to sell for research but not for human use.
The 2026 timeline, accurately#
Section content TBD. Category 2 (2023) → ~12 peptides removed from Category 2 (effective April 23, 2026) → PCAC review (July 23–24, 2026) → formal rulemaking still pending.
Distinctions that get blurred#
Section content TBD. "Removed from Category 2" ≠ "Category 1" ≠ "FDA-approved." CJC-1295 still restricted.
Why the regulated path exists#
Section content TBD. Quality control, sterility, COAs, physician oversight.
How to verify current status#
Section content TBD. Status is still moving — tell readers to confirm with a provider.